Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same

Xanthine derivative defined by chemical Formula I or a salt thereof:

• wherein R1 and R2 are each an optionally substituted group independently selected from hydrogen (—H), (C1-C10)-alkyl, (C2-C10)-alkenyl, (C2-C10)-alkynyl, (C5-C14)-aryl, (C5-C14)-heteroaryl, (C6-C15)-alkyl-arylene, (C6-C15)-alkyl-heteroarylene, (C6-C15)-alkenyl-arylene, (C6-C15)-alkenyl-heteroarylene, (C6-C15)-alkynyl-arylene, (C6-C15)-alkynyl-heteroarylene, (C6-C15)-aryl-alkylene, (C6-C15)-heteroaryl-alkylene, (C6-C15)-aryl-alkenylene, (C6-C15)-heteroaryl-alkenylene, (C6-C15)-aryl-alkynylene and (C6-C15)-heteroaryl-alkynylene,
• wherein the alkyl, alkenyl, alkynyl, alkylene, alkenylene, and alkynylene groups optionally comprise one or more bivalent groups substituting a carbon moiety in their hydrocarbon chain and selected from —O—, —S—, —S(O)—, —SO2—, —N═, —N(R)—, —C(O)—, —C(O)O—,
• —OC(O)—, —C(O)N(R)—, —N(R)C(O)—, —OC(O)N(R)—, —N(R)C(O)O—, —N(R)C(O)N(R)—,
• (C3-C12)-heterocyclic alkylene and (C3-C12)-heterocyclic alkenylene;
• R3 is a group selected from hydrogen (—H), fluoro (—F), bromo (—Br), chloro (—Cl), hydroxyl (—OH), carbonyl (—C(O)R), carboxyl (—C(O)OH), carboxy ester (—CO2R), alkoxy
• (—OR), aldehyde (—C(O)H), trihalide methyl ester (—OCX3), primary, secondary and tertiary amine (—NR(R′)), amide (—N(R)—C(O)—R), imide (—C(O)—N(R)—C(O)—R′), carbamate
• (—N(R)—C(O)—OR′), carboxamide (—C(O)N(R)R′), carbimide (—N(R)—C(O)—N(R′)R″), primary and secondary ketimine (—(R)═NR′), secondary ketimine (—(R)═NH), nitrile (—CN), isonitrile (—NC), nitroxy (—ONO), nitro (—NO2), nitrate (—ONO2), nitroso (—NO), cyanate (—OCN), isocyanate (—NCO), sulfhydryl (—SH), sulfide (—SR), sulfurtrihalide (—SX3), sulfurpentahalide (—SX5), sulfinyl (—S(O)R), sulfonyl (—SO2R), sulfino (—SO2H), and sulfo (—SO3H),
• and an optionally substituted and optionally linked group selected from (C1-C10)-alkyl,
• (C2-C10)-alkenyl, (C2-C10)-alkynyl, (C5-C14)-aryl, (C5-C14)-heteroaryl, (C6-C15)-alkyl-arylene, (C6-C15)-alkyl-heteroarylene, (C6-C15)-alkenyl-arylene, (C6-C15)-alkenyl-heteroarylene, (C6-C15)-alkynyl-arylene, (C6-C15)-alkynyl-heteroarylene, (C6-C15)-aryl-alkylene, (C6-C15)-heteroaryl-alkylene, (C6-C15)-aryl-alkenylene, (C6-C15)-heteroaryl-alkenylene, (C6-C15)-aryl-alkynylene and (C6-C15)-heteroaryl-alkynylene,
• wherein the alkyl, alkenyl, alkynyl, alkylene, alkenylene and alkynylene groups optionally comprise one or more bivalent groups substituting a carbon moiety in their hydrocarbon chain and selected from —O—, —S—, —S(O)—, —SO2—, —N═, —N(R)—, —C(O)—, —C(O)O—,
• —OC(O)—, —C(O)N(R)—, —N(R)C(O)—, —OC(O)N(R)—, —N(R)C(O)O—, —N(R)C(O)N(R)—,
• (C3-C12)-heterocyclic alkylene or (C3-C12)-heterocyclic alkenylene;
• Q is selected from carbon, nitrogen, oxygen,
• sulfur, —*CH2—CH(Rx)—, —*CH═C(Rx)—,
• —*CH2—O—, —*CH2—N(Rx)—, wherein Rx represents hydrogen, methyl, ethyl, cyclopropyl,
• —CH2-cyclopropyl, or halogen, and wherein the carbon marked with an asterisk is covalently linked to the imidazole;
• Z is selected from carbon, nitrogen, oxygen and sulfur;
• the ring member A is an saturated, unsaturated or aromatic ring;
• and
• wherein in the aforementioned definitions R, R′ and R″ independently mean hydrogen,
• (C1-C3)-alkyl or (C2-C3)-alkenyl.